Table S1. Baseline and demographic variables.
| Variable | TAVR | SAVR | P value | |||
|---|---|---|---|---|---|---|
| Patients (n) | Value* | Patients (n) | Value* | |||
| Total | 3,477 | 3,301 | ||||
| Age | 3,275 | 78.08±3.42 | 3,120 | 78.14±3.79 | 0.9 | |
| STS-PROM | 3,275 | 3.82±1.5 | 3,120 | 3.9±1.52 | 0.91 | |
| Male | 3,275 | 1,932 (59.0) | 3,120 | 1,853 (59.4) | 0.76 | |
| CAD | 2,371 | 1,378 (58.1) | 2,271 | 1,317 (58.0) | 0.95 | |
| Diabetes | 3,275 | 1,086 (33.2) | 3,120 | 1,022 (32.8) | 0.75 | |
| Hypertension | 1,734 | 1,518 (87.6) | 1,609 | 1,381 (85.8) | 0.15 | |
| Prior MI | 3,241 | 394 (12.2) | 3,084 | 355 (11.5) | 0.44 | |
| Prior PCI | 2,745 | 572 (20.8) | 2,630 | 550 (20.9) | 0.95 | |
| Peripheral vascular disease | 3,275 | 644 (19.7) | 3,120 | 675 (21.6) | 0.06 | |
| COPD | 2,381 | 468 (19.7) | 2,295 | 468 (20.4) | 0.53 | |
| Cerebrovascular disease | 3,275 | 498 (15.2) | 3,120 | 500 (16.0) | 0.37 | |
| Creatinine >2 mg/dL | 3,275 | 72 (2.2) | 3,120 | 73 (2.3) | 0.74 | |
| Atrial fibrillation | 3,238 | 785 (24.2) | 3,084 | 787 (25.5) | 0.24 | |
| Permanent pacemaker | 3,241 | 242 (7.5) | 3,084 | 240 (7.8) | 0.67 | |
| NYHA III–IV | 3,096 | 1,639 (52.9) | 2,949 | 1,540 (52.2) | 0.59 | |
| Mean AV gradient (mmHg) | 3,275 | 49.96±14.3 | 3,120 | 46.51±8.2 | 0.71 | |
| AV area (cm2) | 3,275 | 0.76±0.06 | 3,120 | 0.76±0.05 | 0.81 | |
| LVEF (%) | 2,266 | 60.0±4.5 | 2,189 | 59.6±5.1 | 0.98 | |
*, data presented as n (%) unless otherwise specified. AV, aortic valve; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.